Article ; Online: Severity and 1-month outcome of SARS-CoV-2 infection in patients with solid cancers: a Danish nationwide cohort study.
Acta oncologica (Stockholm, Sweden)
2021 Volume 60, Issue 7, Page(s) 859–865
Abstract: ... diagnosis.: Methods: This study is a prospective, nationwide study in patients with solid cancer and SARS ... cytotoxic therapy, are associated with adverse outcomes of SARS-CoV-2 infection for patients with solid ... with increased risk for adverse outcomes of SARS-CoV-2 infection for patients with solid cancer. ...
| Abstract | Background: Cancer patients are vulnerable to infections, are older and often have comorbidities in comparison to the general population, which increases the risk for severe outcomes related to COVID-19 diagnosis. Methods: This study is a prospective, nationwide study in patients with solid cancer and SARS-CoV-2 infection included between 10 March to 15 June 2020. Patient's baseline characteristics were collected. The study's primary outcome was overall survival within 30 days of verified SARS-CoV-2 infection. Secondary outcomes were hospital admission, admission to an ICU, and need for supplemental oxygen. Results: A total of 112 patients with a cancer diagnosis and verified SARS-CoV-2 infection were identified. After one month of follow up, hospitalization was required for 54% ( Conclusions: Acknowledging the low sample size in this study, our work shows that age and comorbidities, but not recent cytotoxic therapy, are associated with adverse outcomes of SARS-CoV-2 infection for patients with solid cancer. Particularly, patients with progressive disease seem to be at greater risk of a fatal outcome from COVID-19.HighlightsAge, performance status, and comorbidities are strong predictors of adverse outcome in cancer patients with SARS-CoV-2 infection.Patients with progressive cancer disease seem to be at greater risk of a fatal outcome from COVID-19.Recent cytotoxic therapy, however, did not seem to be associated with increased risk for adverse outcomes of SARS-CoV-2 infection for patients with solid cancer. |
|||||
|---|---|---|---|---|---|---|
| MeSH term(s) | Aged ; COVID-19 ; COVID-19 Testing ; Cohort Studies ; Denmark/epidemiology ; Humans ; Neoplasms/epidemiology ; Prospective Studies ; SARS-CoV-2 | |||||
| Language | English | |||||
| Publishing date | 2021-03-01 | |||||
| Publishing country | England | |||||
| Document type | Journal Article | |||||
| ZDB-ID | 896449-x | |||||
| ISSN | 1651-226X ; 0349-652X ; 0284-186X ; 1100-1704 | |||||
| ISSN (online) | 1651-226X | |||||
| ISSN | 0349-652X ; 0284-186X ; 1100-1704 | |||||
| DOI | 10.1080/0284186X.2021.1889659 | |||||
| Shelf mark |
|
|||||
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Zs.A 6348: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.